TOP
Global
Excipients for Drug Formulation

Crystallization Inhibitors

BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body.

Crystallization inhibition is an important factor to maintain drug solubility and bioavailability out of solid and liquid dosage forms in particular. Before it can be adsorbed, recrystallization can happen at any point in time after formulation, during storage or administration, causing bioavailability to plummet and a consequent loss of medication efficacy. BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body, i.e. our low molecular weight povidones Kollidon® 12 PF and Kollidon® 17 PF or our Kollicoat® MAE 100-55.

Benefits

  • Product range of well established crystallization inhibitors
  • Extensive expertise in overcoming solubilization challenges
  • Trusted functional performance

Discover more about our crystallization inhibition solutions for softgel formulations

Portfolio Overview

Focusing on your needs with platform solutions

Read more

Discover our range of crystallization inhibitors for softgels

Related Solutions